BDX Becton Dickinson and Company

FlowJo and BD to Provide Cloud Platform for Real-Time Single-Cell Marketing Collaboration

FlowJo, LLC, a life science informatics and data analysis company with 20 years of experience in software for analyzing single-cell data, and global medical technology company, BD (Becton, Dickinson and Company) (NYSE:BDX), announced today that they have established a strategic relationship to catalyze the coordination of resources, people and data for the research market.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170613005290/en/

Under the agreement, the companies are collaborating to offer the cloud-based platform, FlowJo Envoy, with BD FACSymphony™, a cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell.* The combination will enable researchers to improve their workflow, collaborations, store their data in the cloud and share single-cell analysis data in real-time.

“After speaking with scientific resource laboratory leaders about their frustrations with coordinating experiments using email threads and social media, we are excited to bring together the BD FACSymphony cell analyzer and FlowJo Envoy to enable scientists to collaborate, coordinate and execute high-parameter single-cell experiments seamlessly in real-time,” said Michael Stadnisky, Ph.D, CEO of FlowJo, LLC.

FlowJo Envoy offers a platform enabling researchers to create and edit a workflow, select instruments for each step, assign steps to collaborators, and upload data and all associated files. Everything is searchable and organized according to the projects and studies the lab is undertaking. In addition, it offers rich comment features and subscriptions to workflow updates so that communication about an experiment stays proximal to the details, SOPs, experimental progress and data.

“Modern application containerization has allowed us to rapidly bring to market a cloud-based platform that will help accelerate research and collaborations on high-parameter flow in a scalable and secure platform,” said Seth Duncan, director of Information Systems and Technology at FlowJo, LLC.

FlowJo and BD made the announcement at CYTO 2017, the 32nd Congress of the International Society for Advancement of Cytometry, being held June 10-14 at the Hynes Convention Center in Boston.

FlowJo Envoy by FlowJo, LLC is available now. For more information about FlowJo Envoy, to request a free trial license, or to get up-to-date training on single-cell data analysis, visit www.flowjo.com.

* The BD FACSymphony system and FlowJo Envoy are intended for Research Use Only and not for use in diagnostic or therapeutic procedures.

About FlowJo, LLC

FlowJo, LLC is a privately-owned life sciences informatics company in Ashland, Oregon. Based on technology developed at Stanford, the company was founded in 1997 and provides the leading analysis platform for single-cell flow cytometry analysis. Their software innovations enable collaboration, discovery, high-throughput analysis, and data leadership in single-cell biology. For more information, see www.flowjo.com.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.

EN
13/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Becton Dickinson and Company

Becton Dickinson & Co: 1 director

A director at Becton Dickinson & Co bought 5,250 shares at 191.570USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Moody's Ratings says Becton Dickinson's separation of Biosciences and ...

Moody's Ratings commented that Becton, Dickinson and Company's (BD, Baa2 stable) separation of its Biosciences and Diagnostic Solutions businesses through a Reverse Morris Trust (RMT) structure is credit negative. The transaction will reduce BD's scale and earnings while increasing its financial lev...

Becton, Dickinson and Company: Separation of Biosciences and Diagnosti...

Impact on the company's credit quality will depend on the type of separation and use of proceeds, but we do not anticipate a change in financial policies.

Becton, Dickinson and Company: Update following closing of critical ca...

Our credit view of this issuer reflects its significant global scale and diversity, offset by its pricing pressure among lower tech products.

Moody’s ratings says Becton's hernia repair settlement is credit negat...

Moody's Ratings (Moody's) commented that Becton, Dickinson and Company's (Baa2 stable) announcement that it had reached an agreement to resolve the vast majority of its US product liability lawsuits involving hernia repair devices is credit negative. Per the settlement terms, Becton will make paymen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch